ÂÜÀòÂÒÂ×

Dr. Sandra Garrett is the Chief Executive Officer of MediMergent, LLC. Prior to co-founding the Company, she served as the Chief Executive Officer of Global Records Systems, LLC, an Electronic Medical Records (EMR) service and software company. Previously, Dr. Garrett served as Executive Chairman of Global Research Services, LLC, a full-service international clinical research organization (CRO) with offices on 3 continents. Dr. Garrett was also the founder of Medifacts International and served as its President and CEO until 2006. Medifacts pioneered the use of 24-hour ambulatory blood pressure monitoring in clinical trials. The Company also pioneered, in alliance with the Max Planck Institute, algorithms for the analysis of QT prolongation as measured by ambulatory 12-lead electrocardiogram (Holter) monitoring. In conjunction with these technologies, Dr. Garrett served as the co-principal investigator with Raymond Lipicky, MD (decd), a past director of the Division of Cardio-Renal Drug Products of the USFDA, under a Cooperative Research and Development Agreement (CRADA). This landmark research defined critical analytics used in the drug approval process for all anti-hypertensive therapies. Dr. Garrett currently serves as the co-principal investigator with Norman Stockbridge, MD, Ph.D., Director of the Division of Cardiovascular and Renal Drug Products, USFDA, under a Research Collaboration Agreement (RCA) focused on the collection and analysis of Real-World Data and Real-World Evidence using disruptive technologies.